Log in to save to my catalogue

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse la...

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse la...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2902948381

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

About this item

Full title

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Publisher

London: Nature Publishing Group UK

Journal title

Bone marrow transplantation (Basingstoke), 2024-03, Vol.59 (3), p.306-314

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a currative treatment modality for diffuse large B-cell lymphoma (DLBCL) because of the intrinsic graft-versus-lymphoma effect. However, limited information is available regarding which patients with relapsed or refractory DLBCL are likely to benefit from allo-HSCT. We retrospectivel...

Alternative Titles

Full title

Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2902948381

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2902948381

Other Identifiers

ISSN

0268-3369,1476-5365

E-ISSN

1476-5365

DOI

10.1038/s41409-023-02156-4

How to access this item